Publications
33
Citations
305
Est. group size
—
Recurring co-author estimate
Active years
27
Publishing since 2000
Hui Yu's work centers on blood cancers, particularly B-cell and T-cell lymphomas, investigating how combinations of targeted drugs (such as BTK, EZH2, HDAC, PI3K, and CDK4/6 inhibitors) can be combined to more effectively kill cancer cells. The publication record also includes more varied topics such as kidney transplant rejection, skin aging from environmental chemicals, bone repair materials, and heart failure biomarkers, suggesting involvement in several collaborative clinical and translational research projects rather than a single narrow focus.
Publication output was minimal before 2020, rose to a peak in 2022, dipped in 2023-2024, and then increased sharply in 2025, indicating an overall growing but uneven publication pace over the past decade.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Protective Effect of Taxifolin Against Monochloroacetic Acid‐Induced Skin Damage via Inhibition of the cGAS/STING/NF‐κB Pathway
Chemistry & Biodiversity · 2025
- Chronic stress-induced downregulation of MFN1 contributes to fatty liver in chickens
Frontiers in Veterinary Science · 2025
- The effects of intragraft CD38+ B cell on chronic active antibody mediated rejection in kidney transplantation
International Urology and Nephrology · 2025
- Chloroacetic acids induce skin aging via cGAS/STING/NF-κB pathway in HaCaT cells, human explants and rats
Ecotoxicology and Environmental Safety · 2025
- Injectable magnesium-bisphosphonate MOF-based bone adhesive prevents excessive fibrosis for osteoporotic fracture repair
Nature Communications · 2025
- EZH2 inhibitor SHR2554 enhances the anti-tumor efficacy of HDAC inhibitor Chidamide through STAT1 in T-cell lymphoma
Cell Death and Disease · 2025
- Association of ST2, Galectin-3, and NT- Probnp in Elderly Hypertensive Patients and Heart Failure with a Preserved Ejection Fraction
Current Vascular Pharmacology · 2025
- PI3K inhibitor idelalisib enhances the anti-tumor effects of CDK4/6 inhibitor palbociclib via PLK1 in B-cell lymphoma
Cancer Letters · 2024
- Management and clinical outcomes of follicular lymphoma across continuous lines of treatments: a retrospective analysis in China
Frontiers in Oncology · 2023
- Additional file 1 of Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy
Open MIND · 2022
- Ibrutinib Combined With Low-Dose HDAC Inhibitor Chidamide Synergistically Enhances the Anti-Tumor Effect in B-Cell Lymphoma
SSRN Electronic Journal · 2022
- The Serum- and Glucocorticoid-Inducible Kinase 1 (SGK1) as a Novel Therapeutic Target in Mantle Cell Lymphoma
Cancer Control · 2022
- Anti‐CD47 immunotherapy in combination with BCL‐2 inhibitor to enhance anti‐tumor activity in B‐cell lymphoma
Hematological Oncology · 2022
- Ibrutinib combined with low‐dose histone deacetylases inhibitor chidamide synergistically enhances the anti‐tumor effect in B‐cell lymphoma
Hematological Oncology · 2022
- Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma
Molecular Therapy — Oncolytics · 2021
- Hematological Oncology×2
- Frontiers in Physiology×2
- American Journal of Hematology×1
- Molecular Therapy — Oncolytics×1
- Nature Communications×1
- Lapo Alinari
Medicine · The Ohio State University
- David A. Bond
Medicine · The Ohio State University
- Beth Christian
Medicine · The Ohio State University
- Kami J. Maddocks
Medicine · The Ohio State University
- Zachary Braunstein
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile